Introduction
============

Urinary tract infection (UTI) is one of the most common community-acquired bacterial infections, and *Escherichia coli* is the predominant causative pathogen for community-acquired UTIs. The current Infectious Diseases Society of America (IDSA) and European Society for Microbiology and Infectious Diseases (ESMID) guidelines as well as guidelines in Korea recommend fluoroquinolones (FQs) as first-line empirical antibiotics for the treatment of UTIs if the local resistance of community uropathogens to FQs is less than 10% \[[@B1][@B2]\]. Unfortunately, the resistance to FQs has been increasing among uropathogenic *E. coli* strains worldwide \[[@B3]\]. Considering that UTIs caused by FQ-resistant *E. coli* can lead to unfavorable clinical outcomes, the increase in FQ-resistant uropathogenic *E. coli* is of great concern \[[@B3]\]. In Korea, the resistance rate of *E. coli* to FQs in community-acquired UTIs has increased from 15.2% in 2002 to 24.8% in 2008 -- 2009 \[[@B4][@B5]\].

There are several possible explanations for the increased prevalence of FQ-resistant uropathogenic *E. coli* isolates in the community. Horizontal gene transfer is an important mechanism for acquiring resistance; *E. coli* becomes resistant to certain antibiotics when resistance genes are transferred via a plasmid \[[@B6]\]. In addition, the increased prevalence may be attributed to the dissemination of clonal organisms containing resistance genes; the spread of ST131 is closely linked to an increase in FQ resistance \[[@B6]\]. Indeed, changes in the molecular epidemiology of *E. coli* have been found to affect the resistance pattern \[[@B7][@B8]\].

The objectives of this study were to investigate the genotypic characteristics and molecular epidemiology of ciprofloxacin-resistant (CIP-R) *E. coli* isolated from community-acquired UTIs in Korea.

Materials and Methods
=====================

1. Study setting {#sec1}
----------------

*E. coli* samples isolated from the blood or urine were collected from patients aged 15 years or more who were admitted to 12 Korean hospitals (3 in Seoul, 4 in Gyeonggi-do, 2 in Incheon, 2 in Daegu, and 1 in Busan) from 1st April 2010 to 29th February 2012. The hospitals had 582 -- 1,250 beds, and 11 of the 12 hospitals were university teaching hospitals. All subjects were diagnosed with community-acquired acute pyelonephritis and recruited prospectively \[[@B9]\]. Only the first isolate from each patient was included in the study. One isolate was collected from each patient.

The study was approved by the Institutional Review Board of Hanyang University Hospital (IRB number: HYUH 2010-007), and the requirement for written informed consent from patients was waived.

2. Antimicrobial susceptibility testing {#sec2}
---------------------------------------

The species and susceptibility to ampicillin (AMP), cefotaxime (CTX), ceftazidime (CAZ), gentamicin (GEN), tobramycin (TOB), and amikacin (AMK) were determined using a semi-automated system \[(VITEK; bioMerieux, Hazelwood, MO, USA) or (MicroScan; DADE Behring, Sacramento, CA, USA)\] in each hospital. Extended-spectrum *β*-lactamase (ESBL)-producing isolates were defined as *Enterobacteriaceae* when identified as positive by the ESBL test in the semi-automated system and/or double disk diffusion test according to the criteria of the Clinical and Laboratory Standards Institute (CLSI) \[[@B10]\]. The minimal inhibitory concentration (MIC) was determined for trimethoprim-sulfamethoxazole (TMP/SMX) by the agar dilution method. Tryptic soy agar (TSA; Difco Laboratories, Detroit, MI, USA) was used with an inoculum of 0.5 McFarland, and quality control was performed using the strain *E. coli* ATCC 25922. Antimicrobial susceptibility to CIP, fosfomycin (FOF), cefepime (FEP), temocillin (TMO), and nitrofurantoin (NIT) was determined by the E-test method (bioMérieux, Marcy-l\'Étoile, France) according to the criteria of the CLSI \[[@B10]\].

3. Characterization of CIP-R *E. coli* isolates {#sec3}
-----------------------------------------------

### 1) Phylogenetic typing and multilocus sequence typing (MLST)

Phylogenetic groups were determined for CIP-R *E. coli* isolates according to the presence of the *chuA* and *yjaA* genes and TspE4.C2 by polymerase chain reaction (PCR) \[[@B11]\]. MLST was conducted as previously described based on the 7 housekeeping genes \[[@B12]\]. Clonal complexes were defined according to the *E. coli* MLST website (<http://mlst.ucc.ie/mlst/dbs/Ecoli/>).

### 2) Molecular characterization of *ß*-lactamase and plasmid-mediated quinolone resistance (PMQR) determinants

PCR and DNA sequence analyses were conducted to determine the genes responsible for ESBL or plasmid-mediated AmpC *ß*-lactamase (PABL) production and the presence of PMQR determinants \[[@B13][@B14]\].

The presence of the *aac(6′)-Ib* gene was investigated by PCR using primers and conditions as previously described \[[@B15]\]. The *aac(6′)-Ib*-positive PCR products were digested with *Bcc*I (Promega, Madison, WI, USA) to identify *aac(6′)-Ib-cr*, which lacks the *Bcc*I restriction site \[[@B15]\]. The wild-type *aac(6′)-Ib* PCR product yielded 233 bp, 209 bp, and 40 bp fragments after restriction digestion.

4. Statistical analysis {#sec4}
-----------------------

SPSS version 24.0 for Windows (IBM Corporation, Armonk, NY, USA) was used for statistical analysis. Categorical variables were analyzed by the Chi-square test or Fisher\'s exact test. A *P* value of \<0.05 (two-tailed test) was considered to be significant.

Results
=======

During the study period, 569 *E. coli* isolates were collected. The number of *E. coli* isolates per hospital ranged from 6 (1.0%) to 144 (25.3%). Among them, 122 (21.4%) isolates were CIP-R isolates.

Of 122 isolates, 25 (20.5%) and 97 (79.5%) were isolated from blood and urine, respectively. The number of isolates from each region was as follows: 84 (68.9%) from Gyeonggi-do, 22 (18.0%) from Daegu, 6 (4.9%) from Busan, 3 (2.5%) from Seoul, and 7 (5.7%) from Incheon.

1. Phylogenetic grouping and MLST analysis {#sec1___1}
------------------------------------------

[Table 1](#T1){ref-type="table"} shows the distribution of the phylogenetic groups of CIP-R *E. coli* isolates. The phylogenetic group B2 was the most common (48.4%, 59/122), followed by D (41.8%, 51/122), B1 (6.5%, 8/122), and A (3.3%, 4/122).

###### Distribution of phylogenetic groups of ciprofloxacin-resistant *Escherichia coli* isolates

![](ic-52-194-i001)

  Phylogenetic group (N)   Sequence type (N)
  ------------------------ -----------------------------------------------------------------------------------------------------------------
  A (4)                    ST393 (1), ST93 (1), ST162 (1), ST602 (1)
  B1 (8)                   ST69 (1), ST10 (3), ST93 (1), ST707 (1), ST744 (1), ST3337 (1)
  B2 (59)                  ST131 (35), ST1193 (16), ST38 (1), ST73 (2), ST95 (1), ST130 (1), ST638 (1), unknown (2)
  D (51)                   ST393 (17), ST38 (10), ST405 (10), ST69 (5), ST117 (2), ST457 (2), ST648 (2), ST68 (1), ST3901 (1), unknown (1)

We identified 22 different sequence types (STs) among 122 CIP-R *E. coli* isolates. The most prevalent ST was ST131 (28.7%, 35/122), followed by ST393 (14.7%, 18/122), ST1193 (13.1%, 16/122), ST38 (9.0%, 11/122), and ST405 (8.2%, 10/122).

All of the ST131 and ST1131 isolates belonged to the phylogenetic group B2, and most of the ST393, ST38, and ST405 isolates belonged to the phylogenetic group D ([Table 1](#T1){ref-type="table"}).

2. Antimicrobial resistance {#sec2___1}
---------------------------

[Table 2](#T2){ref-type="table"} and [Supplementary Table 1](#S1){ref-type="supplementary-material"} shows the antibiotic resistance of CIP-R *E. coli* isolates. Among 122 CIP-R *E. coli* isolates, 60.7% (74/122), 79.5% (93/117), 29.4% (35/119), and 53.8% (64/119) of isolates were resistant to TMP/SMX, AMP, CAZ, and GEN, respectively. On the other hand, less than 5% of isolates were resistant to FOF, NIT, and AMK. A total of 35 (28.7%, 35/122) isolates were ESBL-producing pathogens, and 20 (16.4%, 20/122) isolates showed TMP/SMX resistance concomitantly.

###### Antimicrobial resistance of ciprofloxacin-resistant *Escherichia coli* isolates for five major clones and each phylogenetic group

![](ic-52-194-i002)

  Antibiotics                            Major clones         Phylogenetic groups   Total (%)                                                                                                           
  -------------------------------------- -------------------- --------------------- ---------------- ------------------ ---------------- ------------- ------------ ----------------- ----------------- ---------------
  FOF                                    0/35 (0.0)           0/18 (0.0)            0/16 (0.0)       0/11 (0.0)         0/10 (0.0)       0/4 (0.0)     0/8 (0.0)    0/59 (0.0)        0/51 (0.0)        0/122 (0.0)
  FEP                                    **8/35 (22.9)**^a^   0/18 (0.0)            1/16 (6.3)       3/11 (27.3)        1/10 (10.0)      0/4 (0.0)     0/8 (0.0)    9/59 (15.3)       6/51 (11.8)       15/122 (12.3)
  TMO                                    3/35 (8.6)           0/18 (0.0)            1/16 (6.3)       2/11 (18.2)        1/10 (10.0)      0/4 (0.0)     0/8 (0.0)    5/59 (8.5)        5/51 (9.8)        10/122 (8.2)
  NIT                                    0/35 (0.0)           0/18 (0.0)            0/16 (0.0)       0/11 (0.0)         0/10 (0.0)       0/4 (0.0)     0/8 (0.0)    1/59 (1.7)        0/51 (0.0)        1/122 (0.1)
  TMP/SMX                                17/35 (48.6)         13/18 (72.2)          10/16 (62.5)     9/11 (81.8)        8/10 (80.0)      2/4 (50.0)    5/8 (62.5)   30/59 (50.8)^b^   37/51 (72.5)^b^   74/122 (60.7)
  AMP                                    28/32 (87.5)         11/18 (61.1)          11/16 (68.8)     10/10 (100.0)      10/10 (100.0)    4/4 (100.0)   5/7 (71.4)   45/56 (80.4)      39/50 (78.0)      93/117 (79.5)
  CTX                                    12/30 (40.0)         0/18 (0.0)^a^         0/15 (0.0)^a^    3/10 (30.0)        6/9 (66.7)^a^    1/4 (25.0)    1/6 (16.7)   15/56 (26.8)      15/47 (31.9)      32/113 (28.3)
  CAZ                                    12/30 (40.0)         1/18 (5.6)^a^         0/16 (0.0)^a^    3/11 (27.3)        6/10 (60.0)      3/4 (75.0)    1/7 (14.3)   15/57 (26.3)      16/51 (31.4)      35/119 (29.4)
  GEN                                    20/33 (60.6)         9/18 (50.0)           3/16 (18.8)^a^   11/11 (100.0)^a^   4/10 (40.0)      2/4 (50.0)    2/7 (28.6)   29/57 (50.9)      31/51 (60.8)      64/119 (53.8)
  TOB                                    21/32 (65.6)         9/16 (56.3)           3/16 (18.8)^a^   8/10 (80.0)        4/9 (44.4)       2/4 (50.0)    2/7 (28.6)   30/56 (53.6)      28/46 (60.9)      62/113 (54.9)
  AMK                                    1/31 (3.2)           0/12 (0.0)            0/15 (0.0)       0/10 (0.0)         1/8 (12.5)       0/4 (0.0)     0/6 (0.0)    1/53 (1.9)        3/41 (7.3)        4/104 (3.8)
  ESBL production                        12/35 (34.3)         1/18 (5.6)^a^         0/16 (0.0)^a^    3/11 (27.3)        6/10 (60.0)^a^   3/4 (75.0)    1/8 (12.5)   15/59 (25.4)      16/51 (31.4)      35/122 (28.7)
  ESBL production + TMP/SMX resistance   6/35 (17.1)          1/18 (5.6)            0/16 (0.0)       3/11 (27.3)        4/10 (40.0)^a^   2/4 (50.0)    1/8 (12.5)   7/59 (11.9)       10/51 (19.6)      20/122 (16.4)

FOF, fosfomycin; FEP, cefepime; TMO, temocillin; NIT, nitrofurantoin; TMP/SMX, trimethoprim-sulfamethoxazole; AMP, ampicillin; CTX, cefotaxime; CAZ, ceftazidime; GEN, gentamicin; TOB, tobramycin; AMK, amikacin; ESBL, extended-spectrum beta-lactamase.

^a^*P* \<0.05 and these relate to differences found when susceptibility profiles for isolates of each ST were compared with those all other STs combined.

^b^*P* \<0.05 and these relate to differences found when susceptibility profiles for isolates of each phylogenetic group were compared with those all other phylogenetic groups combined.

In the analysis of resistance according to the ST, the FEP resistance rate of ST131 was significantly higher than that of all other STs combined (22.9% *vs.* 8.0%, *P* = 0.034). The antimicrobial resistance rates of ST393 to CTX (0% *vs.* 33.7%, *P* = 0.004) and CAZ (5.6% *vs.* 33.7%, *P* = 0.016) and its ESBL production rate (5.6% *vs.* 36.2%, *P* = 0.019) were lower than those of all other STs combined. In addition, the AMP resistance rate of ST393 was lower than that of all other STs with marginal significance (61.1% *vs.* 82.8%, *P* = 0.054). The resistance rates of ST1193 were significantly lower than those of all other STs for CTX (0% *vs.* 32.7%, *P* = 0.006), CAZ (0% *vs.* 34.0%, *P* = 0.003), GEN (18.8% *vs.* 59.2%, *P* = 0.003), and TOB (18.8% *vs.* 60.8%, *P* = 0.002). The ESBL production rate of ST1193 was also lower than that of all other STs (0% *vs.* 33.0%, *P* = 0.004). ST38 showed a significantly higher resistance rate to GEN compared with the resistance rate of all other STs combined (100.0% *vs.* 49.1%, *P* = 0.001). The CTX resistance rate (66.7% *vs.* 25.0%, *P* = 0.015) and ESBL production rate (60.0% *vs.* 25.9%, *P* = 0.032) of ST405 were significantly higher than those of all other STs. The prevalence of SXT resistance with ESBL production was higher in ST405 than in all other STs combined with marginal significance (40.0% *vs.* 14.3%, *P* = 0.058).

There were no significant differences in the resistance rates to most antibiotics for each phylogenetic group compared with all others combined. The TMP/SMX resistance rate was lower in the phylogenetic group B2 (50.8% *vs.* 69.8%, *P* = 0.032) and higher in the phylogenetic group D (72.5% *vs.* 52.1%, *P* = 0.023) compared with all other phylogenetic groups combined.

3. Distribution of ESBL/PABL and PMQR determinants {#sec3___1}
--------------------------------------------------

[Table 3](#T3){ref-type="table"} shows the distribution of ESBL/PABL and PMQR determinants among CIP-R *E. coli* isolates. Among 122 CIP-R *E. coli* isolates, ESBL/PABL determinants were found in 35 (28.7%, 35/122) isolates, which belonged to 12 different STs. The most prevalent ESBL/PABL determinant was CTX-M-15 (45.7%, 16/35), followed by CTX-M-14 (40.0%, 14/35). CTX-M-15 was present in 6 different STs (ST131, ST38, ST405, ST117, ST648, and ST130), and CTX-M-14 was also present in 6 different STs (ST131, ST405, ST69, ST10, ST93, and ST457). The prevalence of CTX-M-14 was significantly higher in ST405 than in all other STs combined (40.0% *vs.* 8.9%, *P* = 0.016). In addition, 3 isolates produced both CTX-M-14 and CTX-M-15; 2 of them belonged to ST38. CMY-2 was present in 2 isolates, which belonged to ST393 and ST602 (1.6%, 2/122).

###### Distribution of Extended-spectrum beta-lactamase (ESBL) / Plasmid-mediated AmpC beta-lactamase (PABL) and Plasmid-mediated quinolone resistance (PMQR) determinants of ciprofloxacin-resistant *Escherichia coli* isolates according to multilocus sequence typing (MLST) analysis

![](ic-52-194-i003)

              Major clones                Phylogenetic groups   Total (%)                                                                                                                 
  ----------- --------------------------- --------------------- ------------ ------------ ---------------- ---------------- --------------- ------------ ---------------- --------------- ---------------
  ESBL/PABL                                                                                                                                                                               
              CMY-2                       0/35 (0.0)            1/18 (5.6)   0/16 (0.0)   0/11 (0.0)       0/10 (0.0)       2/4 (50.0)^b^   0/8 (0.0)    0/59 (0.0)       0/51 (0.0)      2/122 (1.6)
              CTX-M-14                    4/35 (11.4)           0/18 (0.0)   0/16 (0.0)   1/11 (9.1)       4/10 (40.0)^a^   0/4 (0.0)       0/8 (0.0)    5/59 (8.5)       9/51 (17.6)     14/122 (11.5)
              CTX-M-15                    8/35 (22.9)           0/18 (0.0)   0/16 (0.0)   0/11 (0.0)       2/10 (20.0)      1/4 (25.0)      1/8 (12.5)   9/59 (15.3)      5/51 (9.8)      16/122 (13.1)
              CTX-M-14 + CTX-M-15         0/35 (0.0)            0/18 (0.0)   0/16 (0.0)   2/11 (18.2)^a^   0/10 (0.0)       0/4 (0.0)       0/8 (0.0)    1/59 (1.7)       2/51 (3.9)      3/122 (2.5)
  PMQR                                                                                                                                                                                    
              *aac(6\')-Ib-cr*            7/35 (20.0)^a^        0/18 (0.0)   0/16 (0.0)   1/11 (9.1)       0/10 (0.0)       1/4 (25.0)      0/8 (0.0)    9/59 (15.3)^b^   1/51 (2.0)^b^   11/122 (9.0)
              *qnrB* + *aac(6\')-Ib-cr*   1/35 (2.9)            0/18 (0.0)   0/16 (0.0)   0/11 (0.0)       0/10 (0.0)       0/4 (0.0)       0/8 (0.0)    1/59 (1.7)       0/51 (0.0)      1/122 (0.01)
              *qnrS* + *aac(6\')-Ib-cr*   0/35 (65.6)           0/18 (0.0)   0/16 (0.0)   0/11 (0.0)       0/10 (0.0)       0/4 (0.0)       0/8 (0.0)    0/59 (0.0)       1/51 (2.0)      1/122 (0.01)

^a^*P* \<0.05 and these relate to differences found when the distribution of ESBL/PABL or PMQR determinants for isolates of each ST were compared with those all other STs combined.

^b^*P* \<0.05 and these relate to differences found when the distribution of ESBL/PABL or PMQR determinants for isolates of each phylogenetic group were compared with those all other phylogenetic groups combined.

PMQR determinants were found in 13 (10.7%, 13/122) CIP-R *E. coli* isolates, which belonged to 5 different STs. *aac(6′)-1b-cr* was the most prevalent PMQR determinant (84.6%, 11/13), and most of the isolates belonged to ST131 (63.6%, 7/11). One ST131 isolate carried *aac(6′)-1b-cr* and *qnrB* concomitantly. Another isolate, which belonged to ST117, carried *aac(6′)-1b-cr* and *qnrS* concomitantly ([Supplementary Table 2](#S2){ref-type="supplementary-material"}).

4. The differences in molecular characteristics of isolates according to specimen or regions {#sec4___1}
--------------------------------------------------------------------------------------------

The proportion of major clones was significantly higher among isolates from urine specimens (52.0% *vs.* 79.4%, *P* =0.006). In comparison, there was no difference in the proportion of each ST. The proportion of isolates that presented ESBL/PABL or PMQR determinants was not significantly different by specimen type.

There was no regional difference in the proportion of major STs between the Metropolitan area (Seoul, Gyeonggi-do, and Incheon) and the Gyeongsang area (Daegu and Busan). CTX-M-15 was more commonly found in the Gyeongsang area than in the Metropolitan area (28.6% *vs.* 7.4%, *P* = 0.006) ([Table 4](#T4){ref-type="table"}).

###### The differences in molecular characteristics of isolates according to specimens or regions.

![](ic-52-194-i004)

                     Specimen           Region                                                  
  ------------------ ------------------ ----------- ----------- ------- ----------- ----------- -------
  Major clones (%)                                                                              
                     ST131              6 (24.0)    29 (29.9)   0.561   27 (28.7)   8 (28.6)    0.988
                     ST393              3 (12.0)    15 (15.5)   1.000   17 (18.1)   1 (3.6)     0.070
                     ST1193             2 (8.0)     14 (14.4)   0.521   12 (12.8)   4 (14.3)    0.760
                     ST38               2 (8.0)     9 (9.3)     1.000   10 (10.6)   1 (3.6)     0.454
                     ST405              0 (0.0)     10 (10.3)   0.212   7 (7.4)     3 (10.7)    0.695
                     Subtotal           13 (52.0)   77 (79.4)   0.006   73 (77.6)   17 (60.7)   0.074
  ESBL/PABL (%)                                                                                 
                     All                5 (20.0)    30 (30.9)   0.281   24 (25.5)   11 (39.3)   0.158
                     CTX-M-14           1 (4.0)     13 (13.4)   0.296   13 (13.8)   1 (3.6)     0.186
                     CTX-M-15           3 (12.0)    12 (12.4)   1.000   7 (7.4)     8 (28.6)    0.006
  PMQR (%)                                                                                      
                     All                4 (16.0)    9 (9.3)     0.465   9 (9.6)     4 (14.3)    0.493
                     *aac(6\')-1b-cr*   4 (16.0)    7 (7.2)     0.234   8 (8.5)     3 (10.7)    0.713

ESBL, Extended-spectrum beta-lactamase; PABL, Plasma-mediated AmpC beta-lactamase; PMQR, plasmid-mediated quinolone resistance.

Discussion
==========

In the present study, we found that 21.4% of *E. coli* isolates associated with community-acquired UTIs in Korea were CIP-R isolates, and ST131, ST393, ST1193, ST38, and ST405 were the major CIP-R uropathogenic *E. coli* clones. The clonal distribution was consistent with the findings of previous studies in Korea. A multicenter study found that ST131 and ST393 were the main clones (24.8% and 17.8% of CIP-R *E. coli*, respectively) in 2006 -- 2007 \[[@B16]\]. Another study demonstrated that ST131 and ST1193 were the major CIP-R *E. coli* clones in 2013 -- 2014 \[[@B17]\].

ST131 is largely responsible for the global dissemination of multidrug-resistant (MDR) *E. coli* strains \[[@B18]\]. The pandemic ST131 has been identified among MDR *E. coli* isolates in several European countries and Asian countries \[[@B18]\]. In Korea, ST131 has emerged as the predominant clone among ESBL-producing or CIP-R *E. coli* isolates from the community and healthcare settings \[[@B9][@B16]\]. The distinctive genetic characteristics of ST131 clones might give them a more competitive edge over other clones, allowing them to rapidly disseminate worldwide \[[@B9]\]. ST131 belongs to the phylogenetic group B2, which is the most virulent group \[[@B18]\]. In addition, ST131 harbors various resistance determinants/genes such as CTX-M-15, TEM-1, OXA-1, and *aac(6′)-1b-cr* \[[@B19]\].

Consistent with the reported genetic characteristics of ST131, we found that ST131 contained several resistance determinants/genes including CTX-M-15, CTX-M-14, and *aac(6′)-1b-cr*. CTX-M-15 and CTX-M-14 are the most widely distributed CTX-M-type ESBL enzymes and are responsible for resistance to penicillins, cephalosporins, and monobactams \[[@B9]\]. *aac(6′)-1b-cr* is a plasmid-mediated gene that encodes a variant of aminoglycoside acetyltransferase, which confers reduced susceptibility to FQs \[[@B20]\]. Several previous studies have demonstrated the close relationship between ST131 and these resistance determinants/genes \[[@B9][@B16][@B21][@B22][@B23]\].

ST393 and ST1193 are also major clones identified among CIP-R *E. coli* isolates in Korea \[[@B16][@B17]\]. Unlike ST131, ST393 is less virulent, which belongs to the phylogenetic group D \[[@B16]\]. They are predominant clonal groups in some regions. In Spain, ST393 was identified as one of the most prevalent MDR *E. coli* clones in extraintestinal infections \[[@B24]\]. In China, ST1193 was reported as the second most abundant FQ-resistant *E. coli* clone \[[@B25]\]. We found that the overall antimicrobial resistance rates of ST393 and ST1193 were significantly lower than the resistance rates of other clones. Furthermore, ESBL or PMQR determinants were largely absent in ST393 and ST1193; only a ST393 clone produced CMY-2. Similar to our findings, previous studies have demonstrated the lower antimicrobial resistance rate and ESBL production activity of ST393 and ST1193 clones \[[@B16][@B17]\]. A study has reported the high resistance rate of ST393 to TMP/SMX \[[@B16]\]. However, the TMP/SMX resistance rate of ST393 was not higher than that of other clones in the present study.

In addition to ST131, ST38 and ST405 are dominant MDR *E. coli* strains \[[@B26]\]. A single-center study in Saudi Arabia revealed the strong association of ST405 with FQ resistance \[[@B26]\]. Another single-center study in Korea found that ST38 and ST405 accounted for 27.5% and 10.0% of CTX-M-producing uropathogenic *E. coli*, respectively \[[@B27]\]. Furthermore, a study in the United Kingdom revealed that most *E. coli* strains carrying the OXA-48 carbapenemase gene belonged to ST38 \[[@B28]\]. Our study found that 60% of ST405 clones were ESBL-producing *E. coli* strains, which was a significantly higher rate compared with the rate for other clones. Notably, we found that 40% (4/10) of ST405 clones produced ESBLs and were co-resistant to TMP/SMX. The MDR characteristic of ST405 is of great concern considering that this will lead to limited treatment options for *E. coli* infection.

Although it is meaningful work to provide basic molecular characteristics of a common causative pathogen for a community-based bacterial infection, the major drawback of this study is the studied isolates were collected 2010 -- 2012 and does not reflect the current situation well. In a prospective observational multi-center study which was conducted in 4 university hospitals in Korea, significantly higher antimicrobial resistance against fluoroquinolone (33.5% *vs.* 21.0%, *P* = 0.001), cefotaxime (34.8% *vs.* 7.6%, *P* \<0.001), and TMP/SMX (37.7% *vs.* 28.4%, *P* = 0.040) were observed for *E. coli* isolates in 2017 -- 2018 compared with those in 2010 -- 2011 \[[@B29]\]. There are possibilities that major clones of *E. coli* strains might have changed in Korea in the last decade. In the France, an increase in ST131, ST38, and ST1193 clones were observed among *E. coli* isolated from UTIs in children from 2014 to 2017 \[[@B30]\]. Further studies on changes in microbiological characteristics in Korea are necessary to clarify this issue.

In the present study, we identified 5 major clones among CIP-R *E. coli* isolates causing community-acquired UTIs in Korea (ST131, ST393, ST1193, ST38, and ST405). ST131, ST38, and ST405 were specifically associated with MDR pathogens. Continuous monitoring of the molecular characteristics of *E. coli* strains and further investigation of the transmission dynamics are necessary.
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